Table 2.
Baseline characteristics and post-PCI treatment of the overall study cohort as well as of patients with and without LV remodelling
| Baseline characteristics | Overall cohort | Remodelling |
||
|---|---|---|---|---|
| n=89 | No (n=75) | Yes (n=14) | p Value | |
| Age, years | 57±10 | 56±10 | 61±10 | 0.134 |
| Female, n (%) | 13 (15) | 10 (13) | 3 (21) | 0.423 |
| Body mass index, kg/m2 | 27±3 | 26±3 | 27±3 | 0.298 |
| Family history for AMI, n (%) | 29 (33) | 26 (35) | 3 (21) | 0.535 |
| Smoking status, n (%) | 46 (52) | 40 (53) | 6 (43) | 0.566 |
| Hypertension, n (%) | 57 (64) | 47 (63) | 10 (71) | 0.763 |
| RRsys, mm Hg | 129±25 | 129±24 | 129±30 | 0.956 |
| RRdia, mm Hg | 80±14 | 80±15 | 78±14 | 0.625 |
| Hyperlipidaemia, n (%) | 55 (62) | 48 (64) | 7 (50) | 0.376 |
| Total cholesterol, mg/dL | 194±41 | 193±37 | 197±58 | 0.830 |
| Diabetes mellitus, n (%) | 7 (8) | 7 (9) | 0 (0) | 0.591 |
| Plasma glucose, mg/dL | 129 (113–155) | 129 (112–151) | 127 (116–161) | 0.900 |
| CKD, n (%) | 5 (6) | 5 (7) | 0 (0) | 0.999 |
| Creatinine, mg/dL | 0.94±0.15 | 0.94±0.15 | 0.91±0.12 | 0.459 |
| eGFR, mL/min/1.73 m2 | 88±16 | 88±16 | 87±18 | 0.956 |
| Ischaemia time, min | 197 (140–404) | 197 (143–390) | 209 (122–483) | 0.799 |
| Anterior STEMI, n (%) | 36 (40) | 26 (35) | 10 (71) | 0.016 |
| Vessel disease, n (%) | 0.022 | |||
| 1 | 49 (55) | 41 (55) | 8 (57) | |
| 2 | 31 (35) | 29 (39) | 2 (14) | |
| 3 | 9 (10) | 5 (7) | 4 (29) | |
| CK max, U/L | 2543±2086 | 2275±1922 | 3974±2409 | 0.005 |
| cTnT max, ng/L | 5303 (2308–7868) | 4303 (1774–7096) | 7675 (5386–15 208) | <0.001 |
| NT-proBNP max, ng/L | 677 (218–1489) | 675 (192–1384) | 784 (606–3658) | 0.070 |
| CRP max, mg/dL | 1.7 (0.9–3.6) | 1.6 (0.9–3.3) | 2.8 (1.4–5.0) | 0.308 |
| Fetuin-A, µg/mL | 568 (478–763) | 581 (484–811) | 518 (447–574) | 0.001 |
| Post-PCI treatment | ||||
| Aspirin, n (%) | 88 (99) | 75 (100) | 13 (93) | 0.157 |
| Clopidogrel, n (%) | 10 (11) | 7 (9) | 3 (21) | 0.189 |
| Prasugrel, n (%) | 74 (83) | 64 (85) | 10 (71) | 0.243 |
| Ticagrelor, n (%) | 5 (6) | 4 (5) | 1 (7) | 0.584 |
| DAPT, n (%) | 88 (99) | 75 (100) | 13 (93) | 0.157 |
| β-Blocker, n (%) | 78 (88) | 66 (88) | 12 (86) | 0.682 |
| Calcium channel blocker, n (%) | 3 (3) | 3 (4) | 0 (0) | 0.999 |
| ACE inhibitor, n (%) | 73 (82) | 61 (81) | 12 (86) | 0.999 |
| AT1-antagonist, n (%) | 8 (9) | 8 (11) | 0 (0) | 0.347 |
| Statin, n (%) | 89 (100) | 75 (100) | 14 (100) | – |
AMI, acute myocardial infarction; AT1, angiotensin II receptor type 1; CK, creatine kinase; CKD, chronic kidney disease; CRP, C reactive protein; cTnT, cardiac troponin T; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; LV, left ventricular; max, maximum; NT-proBNP, N-terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; RRdia, diastolic blood pressure; RRsys, systolic blood pressure; STEMI, ST segment elevation myocardial infarction.